1. France Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
ABIONYX Pharma SA

ABIONYX Pharma SA

1.62
EUR
+0.03
(+2.15%)
135.70MMarket Cap
Mar 16Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
0.01
- -
- -
0.03
0.18
0.14
0.13
0.12
- -
Basic EPS, GAAP
-0.58
-0.49
-0.99
-1.37
-0.27
-0.33
0.09
-0.08
-0.23
-0.15
-0.11
-0.12
-0.16
- -
Free Cash Flow per Basic Share
-1.09
-0.25
-0.82
-1.06
-0.5
-0.32
-0.19
-0.03
-0.27
-0.12
-0.12
-0.11
-0.09
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.45
- -
1.84
0.79
0.48
0.2
0.3
0.27
0.38
0.25
0.24
0.21
0.13
0.13
Tangible Book Value per Share
0.45
- -
1.84
0.79
0.47
0.19
0.3
0.27
0.19
0.06
0.08
0.06
-0.03
-0.03
Basic Weighted Avg Shares
13
13
17
18
19
19
21
23
25
28
33
35
35
35
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
1
5
5
5
4
- -
Operating Margin (%)
- -
- -
- -
- -
- -
-4,005.17
- -
- -
-869.48
-75.7
-68.21
-94.99
-133.6
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-8
-7
-17
-25
-5
-6
2
-2
-6
-4
-4
-4
-6
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
2.01
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-3,623.56
- -
- -
-862.52
-80.08
-75.82
-96.26
-136.6
- -
Working Capital
11
6
40
22
15
4
7
6
6
2
3
2
- -
- -
LT Debt
4
5
6
7
6
1
- -
- -
4
3
3
2
3
3
Total Equity
6
- -
33
15
9
4
7
7
11
7
8
8
5
5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-28.67
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
25.5
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-212.6
-100.2
-104.04
-42.37
-99.09
35.21
-28.37
-67.28
-47.14
-46.62
-56.76
-92.29
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
1
- -
1
LT Borrowings
1
- -
2
LT Finance Leases
1
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
35
35
36
Market Capitalization
42
43
136

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
6
- -
5
Cash, Cash Equivalents & STI
3
- -
4
Accounts Receivable, Net
1
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
4
- -
5
Payables & Accruals
- -
- -
- -
ST Debt
1
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-8.52%
-1.28%
-39.96%
Free Cash Flow
59.64%
152.08%
-14.42%
Net Income, GAAP
-11.94%
43.16%
26.68%
Sales/Revenue/Turnover
- -
- -
-10.72%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
5
2024
- -
- -
5
2025
- -
- -
4

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.11
2024
- -
- -
-0.12
2025
- -
- -
-0.16

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Cyrille Tupin
Full Time Employees
49
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building D2 Balma OC France 31130
IPO Date
Mar 30, 2015
Website
abionyx.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
ABIONYX Pharma SA (ABNX.PA) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative apoA-I-based therapies for severe diseases lacking effective treatments, including sepsis, renal disorders, ophthalmological conditions, and metabolic diseases such as non-alcoholic steatohepatitis (NASH). The company offers CER-001, an engineered high-density lipoprotein (HDL) particle containing recombinant human apoA-I with sphingomyelin and dipalmitoylphosphatidylglycerol phospholipids that mimics pre-beta HDL to address inflammation, acute kidney injury, and immune dysregulation in sepsis and post-acute coronary syndrome; CER-002, a peroxisome proliferator-activated receptor delta agonist targeting cardiovascular and metabolic indications; and CER-209, a P2Y13 receptor agonist drug candidate for NASH, atherosclerosis, liver metabolic diseases, and related conditions; alongside HDL vectors for targeted drug delivery in oncology and ophthalmology. ABIONYX Pharma operates primarily in Europe with clinical activities extending to the United States and global partnerships, targeting patients with critical care needs, rare genetic disorders like LCAT deficiency (Norum disease), and underserved therapeutic areas in biotechnology. Founded in 2005 and headquartered in Balma, France, the company, formerly Cerenis Therapeutics Holding SA until its name change in August 2019, employs approximately 51 people under CEO Cyrille Tupin. Recent developments include an exclusive global strategic partnership with SEBIA announced in November 2025 to advance sepsis diagnostics using apoA-I biomarkers; advanced strategic discussions with IHU SEPSIS, the world's leading sepsis research center, also in November 2025; the start of talks in August 2025 with a major sepsis player for CER-001 commercialization; a €8.7 million award from the French government's France 2030 i-Démo plan in February 2025 to combat sepsis; positive EMA feedback in 2024 for CER-001 in LCAT deficiency; and the appointment of Rob Scott, MD, as Chief Medical Officer in early 2024 to lead R&D expansion.